Gender-affirming estrogen therapy (GAET) is commonly used for feminization in transgender
and nonbinary (TNB) individuals, yet the optimal rate of change (ROC) in estradiol levels for …

Venous thromboembolism is a documented risk of some estradiol formulations, but evidence
evaluating the perioperative risk of continuation of estradiol therapy is limited. This narrative …

Since the Sustainable Development Goals were adopted by the United Nations in 2015 and
became well known, the recognition of transgender and gender-diverse populations has …

Background: Previous studies have cross-sectionally described amenorrhea in cohorts of
transgender men on intramuscular or subcutaneous testosterone injections. It remains …

Aims Feminizing gender‐affirming hormone therapy (GAHT) can be utilized to help
transfeminine transgender and gender diverse (TGD) individuals achieve the transformation …

Transgender individuals represent a medically underserved and under researched
population. There is a growing number of studies illustrating the importance of hormone …

Background Transgender women receiving estrogen as part of gender-affirming hormone
therapy are at increased cardiovascular risk (CV). Non-oral, compared to oral, estrogen …

Purpose Gender-affirming hormone treatment (GAHT) is one of the main demands of
transgender and gender diverse (TGD) people, who are usually categorised as transgender …

Background The transgender population is rapidly growing in the United States and abroad.
Transgender men and women are marginalized as a result of their transgender status, with …

With the growing number of transgender and gender-nonbinary individuals who are
becoming visible, it is clear that there is a need to develop a rigorous evidence base to …